medigraphic.com
ISSN 1560-4381 (Print)

2015, Number 4

<< Back Next >>

Correo Científico Médico 2015; 19 (4)

Cyclophosphamide in the systemic sclerosis treatment

Remedios BSE, Velázquez GA, Del Campo AE, Torres PL, Fernández PA

Language: Spanish
References: 32
Page: 1-12
PDF size: 117.92 Kb.


ABSTRACT

A search on the history of different therapies use in patients with systemic sclerosis was done, the advantages of the use of cyclophosphamide was approached, therapeutic failure and tested, present and future possibilities, in order to demonstrate the advantages of using cyclophosphamide as first-line therapy in patients included in different studies, and sensitize the scientific community of the specialty of rheumatology, on the risk benefit of using this drug in patients with a disease of a very poor prognosis . The selection of patients with systemic sclerosis will undergo treatment with cyclophosphamide in controlled studies required preclinical or early phases without any of its existing clinical forms exclusion, irreversibility showing severe forms of the disease, as well as the period duration of two years less medication could be causes of treatment failure. The results of this comprehensive review motivate the scientific community to insist on how to use it.


REFERENCES

  1. Chan PT, Mok CC. Pauci -immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis. Clin Rheumatol.2012 [citado 23 mar 2013]; 31(8):1273-7. Disponible en: http://dx.doi.org/10.1007/s10067-012-2010-8

  2. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheumatology (Oxford).2010 [citado 23 may 2015]; 49 (12):2375-80. Disponible en:http://www.ncbi.nlm.nih.gov/pubmed/?term=Mobilization+of+endothelial+progenitor+cells+b y+intravenous+cyclophosphamide+in+patients+with+systemic+sclerosis

  3. Miniati I, Valentini G, Cerinic MM. Cyclophosphamide in systemic sclerosis: still in search of a ‘real life’ scenario Published. Arthritis Res Ther. 2009 [citado 12 dic 2014]; 11(1).Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Cyclophosphamide+in+systemic+sclerosis%3A+still +in+search+of+a+%E2%80%98real+life%E2%80%99+scenario+Published

  4. Valentini G, Vettori S, Cuomo G, Iudici M, D'Abrosca V, Capocotta D, et al. Early Systemic Sclerosis: short- term disease evolution and factor predicting the development of new manifestations of organ involvement. Arthritis Res Ther. 2012. [Citado 28 ene 2015]; 14(4). Disponible en: http://www.arthritis-research.com/content/14/4/R188

  5. Walker KM, Pope J. Treatment of Systemic Sclerosis Complications: What to Use When First- Line Treatment Fails-A Consensus of Systemic Sclerosis Experts. Semin Arthritis Rheum.2012 [citado 25 jun 2015]; 42(1):42-55. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22464314

  6. Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets. Curr Pharm Des.2012 [citado 28 ene 2015]; 18(11):1457-64. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Systemic+sclerosisrelated+ pulmonary+hypertension%3A+unique+characteristics+and+future+treatment+targets

  7. Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, et al. Adverse events during the Scleroderma Lung Study. Am J Med.2011 [citado 23 mar 2011]; 124 (5):459-67. Disponible en: http://www.sciencedirect.com/science/article/pii/S0002934311000556

  8. Sakurai K, Otsuka A, Miyachi Y, Kabashima K. Fixed drug eruption induced by Cyclophosphamide. Eur J Dermatol. 2012 [citado 22 may 2014]; 22(3):401-2. Disponible en: http://www.jle.com/fr/revues/ejd/edocs/ fixed_drug_eruption_induced_by_cyclophosphamide_293038/article.phtml

  9. Espinosa G, Simeón CP, Plasín MÁ, Xaubet A, Muñoz X, Fonollosa V, et al. Efficacy of cyclophosphamide in the treatment of interstitial lung disease associated with systemic sclerosis. Arch Bronconeumol.2011 [citado 10 ene 2015]; 47 (5):239-45. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21458128

  10. Pérez D, Estévez Del Toro M, Peña Casanovas A, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR. ¿Son necesarias las dosis elevadas de prednisona para el tratamiento de la neumopatía intersticial en la esclerosis sistémica?. Reumat Clin.2012 [citado 7 ene 2015]; 8 (2):58-62. Disponible en: http://www.reumatologiaclinica.org/en/are-high-doses-prednisonenecessary/ articulo/S2173574312000329/

  11. Takahashi T, Asano Y, Amiya E, Hatano M, Tamaki Z, Ozeki A, et.al. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Mod Rheumatology.2012 [citado mar 23 2014]; 22(4):598- 601.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22015621

  12. Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009 [citado 23 mar 2015]; 48(1):49-52. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18815156

  13. Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of Systemic Sclerosis-Associated Calcinosis: A Case Report of Rituximab-Induced Regression of CREST-Related Calcinosis and Review of the Literature. Semin Arthritis Rheum. 2012 [Citado 23 mar 2014]; 41(6):822-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22221908

  14. C Vonk M, H J van den Hoogen F, L C M van Riel P, Valentini G. What does the clinician need to improve patient care in systemic sclerosis? Ann Rheum Dis. 2007 [Citado 23 mar 2014]; 66(9):1129–1131. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1955166/

  15. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al.The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol.2003 [citado 23 mar 2014]; 22(4-5):289-94.Disponible en: http://dx.doi.org/10.1007/s10067-003- 0733-2.

  16. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, Craig R, et al. Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet.2011 [citado 6 dic 2014]; 378 (9790):498-506. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21777972

  17. Toledano C, Henegar C, Ilie D, Launay D, Tiev K, Marie I, et al. Cardiopulmonary function before and after cyclophosphamide treatment in severe systemic sclerosis: comparison of monthly intravenous bolus and autologous hematopoietic stem cell transplantation. Rev Med Interne. 2005 [citado 25 abr 2014]; (6):444-52. Disponible en: http://www.ncbi.nln.nih.gov/pubmed?termtoledano.

  18. Farge D, Gluckman E. Autologous HSCT in systemic sclerosis: a step forward. Lancet. 2011 [citado 6 ene 2015]; 378 (9790):460-2. Disponible en: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2961100- 8/fulltext?rss=yes

  19. Gonzalez Nieto JA, Martin Suarezb IJ, Gil Muñoz FL. Efficacy of Mycophenolate associated with methotrexate as a maintenance treatment for systemic sclerosis-associated interstitial lung disease. Arch Bronconeumol. 2011 [citado 27 abr 2014]; 47(11).Disponible en: http://www.archbronconeumol.org/en/efficacy-of-mycophenolate-associatedwith/ articulo/90069577/

  20. Anton JM, Castro P, Espinosa G, Marcos M, Gandia M, Merchan R, et al. Mortality and long term survival prognostic factors of patients with systemic autoimmune diseases admitted to an intensive care unit: a retrospective study. Clin Exp Rheumatol.2012 [citado 6 dic 2014]; 30(3):338-44 Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22338619

  21. Chakravarty E. Pre-disease pregnancy complications and systemic sclerosis: pathogenic or pre-clinical? Arthritis Res There. 2012 [citado 19 abr 2015];14(1). Disponible en: http://www.arthritis-research.com/content/pdf/ar3686.pdf

  22. Mouthon L, Bérezné A, Guillevin L, Valeyre D. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respire Med. 2010 [citado 25 abr 2014]; 104(1):59- 69.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20630349

  23. Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P. PHigh-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis. 2009 [citado 16 abr 2015]; 12(3):239-42. Disponible en: http://dx.doi.org/10.1111/j.1756-185x.2009.01417.x

  24. Masuii Y, Asano Y, Takahashi T, Shibata S, Akamata K, Aozasa N, et.al. Clinical significance of monitoring serum adiponectin levels during intravenous pulso cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatol.2013 [citado 19 mar 2015]; 23(2):323-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22610787

  25. Tochimoto A, Kawaguchi Y, Hara M, Tateishi M, Fukasawa C, Takagi K, et al.Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol. 2011[citado 23 feb 2015]; 21(3):296-301. Disponible en: http://link.springer.com/article/10.1007%2Fs10165- 010-0403-6#/page-1

  26. Yamada D, Asano Y, Takahashi T, Masui Y, Aozasa N, Akamata K, et al. Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis. Eur J Dermatol. 2012 [citado 14 de ene 2015]; 22(3):351-7.Disponible en: http://www.jle.com/en/revues/ejd/edocs/ clinical_significance_of_serum_decoy_receptor_3_levels_in_patients_with_systemic_sclerosi s_293022/article.phtml

  27. Au K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, et al. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care Res (Hoboken). 2010 [citado 18 ene 2015]; 62(12):1772-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20740615

  28. Schulz SW, O'Brien M, Maqsood M, Sandorfi N, Del Galdo F, Jimenez SA. Improvement of severe systemic sclerosis-associated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide. J Rheumatol. 2009 [citado 18 ene 2015]; 36 (8):1653-6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19605670

  29. Moore J, Englert H, Furlong T, Poon T, Milliken S, Ma D. Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide. Bone Marrow Transplant. 2012 [citado 21 ene 2015]; 47 (11):1486-7. Disponible en: http://www.nature.com/bmt/journal/v47/n11/full/bmt201267a.html

  30. Hosing C, Nash R, McSweeney P, Mineishi S, Seibold J, Griffith LM, et al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. Biol Blood Marrow Transplant. 2011 [citado 12 feb 2015]; 17 (5):674-81. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20708086

  31. Sakellari I, Gavriilaki E, Mallouri D, Batsis I, Anagnostopoulos A. Autologous HSCT for systemic sclerosis. Lancet. 2013 [citado 25 abr 2015]; 381 (9883). Disponible en: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961240-4/fulltext

  32. Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F, Kanz L, et al. Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center long term experience in 26 patients with severe organ manifestations. J Rheumatol. 2012 [citado 25 abr 2015]; 39(2):269-75. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22247352




2020     |     www.medigraphic.com